DRUG FY2025 EPS Forecast Lifted by Cantor Fitzgerald

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of Bright Minds Biosciences in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($0.64) for the year, up from their prior forecast of ($0.87). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Bright Minds Biosciences' current full-year earnings is ($1.24) per share. Cantor Fitzgerald also issued estimates for Bright Minds Biosciences' FY2026 earnings at ($0.75) EPS.

Other analysts also recently issued reports about the company. Wall Street Zen downgraded Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Chardan Capital reiterated a "buy" rating and issued a $80.00 price target on shares of Bright Minds Biosciences in a report on Wednesday, May 21st. Cowen assumed coverage on shares of Bright Minds Biosciences in a report on Tuesday, May 13th. They set a "buy" rating on the stock. TD Cowen assumed coverage on shares of Bright Minds Biosciences in a report on Tuesday, May 13th. They issued a "buy" rating for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $85.00 price target on shares of Bright Minds Biosciences in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $83.25.

Bright Minds Biosciences Price Performance

Shares of NASDAQ:DRUG traded up $0.27 during trading on Wednesday, reaching $28.02. The company had a trading volume of 2,569 shares, compared to its average volume of 821,928. Bright Minds Biosciences has a fifty-two week low of $0.93 and a fifty-two week high of $79.02. The stock's fifty day moving average price is $30.40 and its 200 day moving average price is $35.00. The firm has a market capitalization of $197.37 million, a price-to-earnings ratio of -164.81 and a beta of -5.75.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.10.

Institutional Investors Weigh In On Bright Minds Biosciences

Several institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE bought a new stake in Bright Minds Biosciences during the fourth quarter worth approximately $173,000. Jane Street Group LLC acquired a new position in shares of Bright Minds Biosciences during the 4th quarter valued at $238,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Bright Minds Biosciences in the 1st quarter worth $505,000. Atika Capital Management LLC acquired a new stake in shares of Bright Minds Biosciences in the fourth quarter valued at $540,000. Finally, Goldman Sachs Group Inc. bought a new stake in Bright Minds Biosciences in the first quarter worth about $802,000. Institutional investors and hedge funds own 40.52% of the company's stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.